
    
      OBJECTIVES:

      Primary

        -  To determine the response rate to capecitabine and oxaliplatin in patients with locally
           advanced or metastatic pancreatic adenocarcinoma Secondary

        -  To determine safety

        -  To determine overall survival

        -  To determine time to progression
    
  